TNFRSF17 and neoplasm: Anti-BCMA BAFF-R CAR T cell treatment significantly enhanced mouse survival over 100 days compared to the 4-1BB CAR 100 days post tumor cell injection (Mantel Cox test, p<0.05; Fig. 7D).